糖尿病与非酒精性脂肪性肝病*

doi:10.3969/j.issn.1672-5069.2022.03.003

摘要/Abstract

关键词: 非酒精性脂肪性肝病, 2型糖尿病, 胰高血糖素样肽-1, 法尼醇X受体

Key words: Non-alcoholic fatty liver diseases, Diabetes mellitus type 2, Glucagon-like peptide-1, Farnesoid X receptor

年福临, 鲁晓岚. 糖尿病与非酒精性脂肪性肝病^*[J]. 实用肝脏病杂志, 2022, 25(3): 314-317.

Nian Fulin, Lu Xiaolan. Non-alcoholic fatty liver disease and diabetes mellitus type 2[J]. Journal of Practical Hepatology, 2022, 25(3): 314-317.

[1] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志, 2007, 10(1): 1-3.
[2] Younossi Z M. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol, 2019, 70(3): 531-544.
[3] Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022, 183:109119.
[4] Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med, 2018, 283(4): 356-370.
[5] Xu J Y, Yang L B, Han Z Y, et al. Appropriate body mass index cutoffs for type 2 diabetes in Xinjiang population: defining the influence of liver aminotransferase. Oncotarget, 2021, 12(14): 1398-1405.
[6] Younossi Z M, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J Hepatol, 2019, 71(4): 793-801.
[7] 邵勇, 徐静远, 鲁晓岚, 等. 非酒精性脂肪性肝病增加2型糖尿病发病率:一项基于苏南某镇农村老年人群的队列研究.中华肝脏病杂志, 2021, 29(09): 867-872.
[8] Pang Y, Kartsonaki C, Turnbull I, et al. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. Hepatology, 2018, 68(4): 1308-1318.
[9] Mantovani A, Rigolon R, Mingolla L, et al. Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. J Diabetes Complications, 2017, 31(6): 1021-1026.
[10] Mangla N, Ajmera V H, Caussy C, et al. Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol, 2020, 18(3): 744-746.
[11] Kitagawa N, Hashimoto Y, Hamaguchi M, et al. Liver Stiffness Is Associated With Progression of Albuminuria in Adults With Type 2 Diabetes: Nonalcoholic Fatty Disease Cohort Study. Can J Diabetes, 2020, 44(5): 428-433.
[12] Wan Y, Garner J, Wu N, et al. Role of stem cells during diabetic liver injury. J Cell Mol Med, 2016, 20(2): 195-203.
[13] 张永超, 李威. 糖尿病和非酒精性脂肪性肝病相关肝细胞癌的相互关系.临床肝胆病杂志, 2020, 36(10): 2329-2332.
[14] Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest, 2005, 115(5): 1139-1142.
[15] Roden M, Shulman G I. The integrative biology of type 2 diabetes. Nature, 2019, 576(7785): 51-60.
[16] Tilg H, Adolph T E, Moschen A R. Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade. Hepatology, 2021, 73(2): 833-842.
[17] Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet, 2003, 361(9353): 226-228.
[18] Kim K, Kang J K, Jung Y H, et al. Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nat Commun, 2021, 12(1): 1822.
[19] Hedjazifar S, Khatib Shahidi R, Hammarstedt A, et al. The Novel Adipokine Gremlin 1 Antagonizes Insulin Action and Is Increased in Type 2 Diabetes and NAFLD/NASH. Diabetes, 2020, 69(3): 331-341.
[20] Wu X, Shu L, Zhang Z, et al. Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells. Adv Sci (Weinh), 2021, 8(11): e2003721.
[21] Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep, 2019, 1(4): 312-328.
[22] 李川, 李莉. 2型糖尿病合并非酒精性脂肪性肝病的研究及治疗进展.中国继续医学教育, 2019, 11(04): 114-116.
[23] Yung J H M, Giacca A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells, 2020, 9(3): 706
[24] Solinas G, Becattini B. JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab, 2016, 6(2): 174-184.
[25] Roshanzamir F, Miraghajani M, Rouhani M H, et al. The association between circulating fetuin-A levels and type 2 diabetes mellitus risk: systematic review and meta-analysis of observational studies. J Endocrinol Invest, 2018, 41(1): 33-47.
[26] Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism, 2019, 101:153994.
[27] 任士萌, 梅璐, 黄煌, 等.非酒精性脂肪性肝病患者肠道菌群及生物化学指标相关性分析.中华肝脏病杂志, 2019, 27(05): 369-375.
[28] Alexander M, Loomis A K, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med, 2019, 17(1): 95.
[29] Kanwal F, Kramer J R, Li L, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 71(3): 808-819.
[30] Simon T G, King L Y, Chong D Q, et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.Hepatology, 2018, 67(5): 1797-1806.
[31] Berrou J, Fougeray S, Venot M, et al. Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One, 2013, 8(4): e62418.
[32] Wolf M J, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8⁺T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer Cell, 2014, 26(4): 549-564.
[33] Ma C, Kesarwala A H, Eggert T, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531(7593):253-257.
[34] Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne), 2014, 5:10.
[35] Schwabe R F, Greten T F. Gut microbiome in HCC - Mechanisms, diagnosis and therapy. J Hepatol, 2020, 72(2):230-238.
[36] Matson V, Chervin C S, Gajewski T F. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology, 2021, 160(2): 600-613.
[37] 刘志平, 赵致维, 张金华. 非酒精性脂肪性肝病患者肠道菌群与胰高血糖素样肽1的相关性分析. 临床肝胆病杂志, 2020, 36(01): 136-139.
[38] Hogan A E, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia, 2014, 57(4): 781-784.
[39] Lee Y S, Park M S, Choung J S, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia, 2012, 55(9): 2456-2468.
[40] Fang Q H, Shen Q L, Li J J, et al. Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. Hepatol Res, 2019, 49(7): 743-757.
[41] Kasumov T, Li L, Li M, et al. Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis. PLoS One, 2015, 10(5): e0126910.
[42] Xu X, Shi X, Chen Y, et al. HS218 as an FXR antagonist suppresses gluconeogenesis by inhibiting FXR binding to PGC-1α promoter. Metabolism, 2018, 85:126-138.

糖尿病与非酒精性脂肪性肝病^*

Non-alcoholic fatty liver disease and diabetes mellitus type 2

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[2]	蔡冬梅, 吴文娟, 姜亦伦, 居敏昊. CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 383-386.
[3]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[4]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[5]	陈凯, 居峰. 多烯磷脂酰胆碱联合扶正化瘀片治疗非酒精性脂肪性肝病患者肝脏超声脂肪变性评分变化^*[J]. 实用肝脏病杂志, 2022, 25(2): 219-222.
[6]	梁烨倍, 杨春光, 王昆凤, 胡秋明, 李妍辉, 罗琴, 陈浩, 郑亚雄, 余俊, 唐小英, 史华祥, 牛涛, 吴伟, 侯旭宏, 贾伟平. 云南省布朗族成人非酒精性脂肪性肝病流行特点研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 223-226.
[7]	李伟, 黄宇, 钟璟, 韦隽. 外周血PNPLA3 rs738409基因多态性与非酒精性脂肪性肝病遗传易感性研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 227-230.
[8]	莫超艳, 杨有强, 钟嫄, 肖友雪. 非酒精性脂肪性肝病合并2型糖尿病患者血清抵抗素和黄醇结合蛋白4水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 231-234.
[9]	王芳, 高晓霞, 汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 235-238.
[10]	黄蝶, 田昊宇, 李异玲. 非酒精性脂肪性肝病血清标志物研究进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 297-300.
[11]	吕春卉, 李大炜, 王小洁, 康晓平, 韩宗晟, 朱允. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2022, 25(1): 50-53.
[12]	任洁, 郝巧歆, 黄成河, 陈勋, 卢欣. 非酒精性脂肪性肝病合并T2DM患者肠道菌群结构变化研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 54-57.
[13]	顾雪香, 李祥玉, 单勤星. 柴胡皂苷a通过影响PPARα信号通路对非酒精性脂肪性肝病大鼠肝脂肪变的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(6): 807-810.
[14]	朱南南, 蒋晓红, 周佳雁, 黄小琳, 刘雅旻. 2型糖尿病合并代谢相关性脂肪性肝病患者血尿酸水平变化和其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 839-842.
[15]	葛海燕, 匡霞, 周瑞君. 非酒精性脂肪性肝病合并2型糖尿病患者外周血miR-17、miR-20a和miR-20b变化及其临床意义^*[J]. 实用肝脏病杂志, 2021, 24(5): 697-700.